| Age (year) |
38.0 ± 10.4 |
| Male/Female |
51 (75%)/17 (25%) |
| Type of donor (deceased/living) |
24 (35.3%)/44 (64.7%) |
| Cause of end-stage renal disease |
|
| Glomerulonephritis |
9 (13.2%) |
| Obstructive uropathy/chronic pyelonephritis |
5 (7.4%) |
| ADPKD |
2 (2.9%) |
| Hypertension |
2 (2.9%) |
| Others |
3 (4.4%) |
| Unknown |
47 (69.1%) |
| Type of dialysis |
|
| Hemodialysis/Peritoneal dialysis |
42/27 |
| Duration of dialysis (mo) |
|
| Hemodialysis |
26 (8-108) |
| Peritoneal dialysis |
24 (5-240) |
| Post-transplant duration (mo) |
24 (1-252) |
| Systolic blood pressure (mmHg) |
128 ± 16 |
| Diastolic blood pressure (mmHg) |
88 ± 14 |
| Presence of post-transplant diabetes mellitus |
8 (11.3%) |
| Presence of post-transplant hypertension |
56 (78.9%) |
| History of acute allograft rejection |
10 (14.7%) |
| Creatinine clearance (mL/min) |
66.3 ± 28.5 |
| Use of |
|
| Steroid |
67 (98.5%) |
| Tacrolimus |
41 (60.3%) |
| Cyclosporine |
20 (29.4%) |
| Mycophenolate |
50 (73.5%) |
| Azathioprine |
13 (19.1%) |
| Sirolimus |
6 (8.8%) |
| ACEI or ARB |
21 (30.9%) |
| Vitamin D |
20 (29.4%) |
ADPKD: Autosomal-Dominant Polycystic Kidney Disease; ACEI: Angiotensin
Converting Enzyme İnhibitor; ARB: Angiotensin II Receptor Blocker